FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC

Oncology (Williston Park). 2020 Feb 20;34(2):44.

Abstract

The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • BCG Vaccine / administration & dosage*
  • Clinical Trials, Phase II as Topic
  • Drug Approval*
  • Drug Resistance, Neoplasm
  • Humans
  • Multicenter Studies as Topic
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Survival Rate
  • United States
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / pathology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • BCG Vaccine
  • pembrolizumab